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Kathryn B. Garber1,*Treatment for Vascular Ehlers-Danlos Syndrome
If you try to blow up a balloon with a weak spot, the weak
spot gets bigger and—if you keep blowing—it’s likely to
burst. This is basically a simplified model of the connective
tissue disorder vascular Ehlers-Danlos syndrome (EDS); the
pressure and mechanical stress put on fragile tissues with
defective type III collagen can lead to vascular or hollow
organ rupture. This model led to the underlying premise
of the BBEST trial, a prospective study to determine the
effect of beta-blockers on vascular EDS: would reducing
the heart rate and pulsatile pressures decrease the vascular
complications associated with vascular EDS? The trial, in
which affected individuals were randomly assigned to
a group who received the hypertension drug celiprolol or
to a control group, was planned as a five-year trial. Ong
et al. recently reported the results of the trial, which was
stopped early because of treatment benefit. Celiprolol
treatment resulted in a 64% reduction in the risk of amajor
complication of vascular EDS, such as arterial rupture or
dissection. The effect of celiprolol occurred despite the
fact that the original rationale for the trial did not hold
true; the drug did not reduce the heart rate or blood pres-
sure of treated patients. This does not negate the risk reduc-
tion conferred by celiprolol treatment; it simply means
that there is more to learn about the pathogenic process
of vascular EDS.
Ong et al. (2010) Lancet. Published online September 7,
2010. 10.1016/S0140-6736(10)61155-5
When a Loss Is a Gain
Contractions of a D4Z4 repeat sequence in the subtelo-
meric region of chromosome 4q cause facioscapulohum-
eral muscular dystrophy (FSHD), a progressive muscular
dystrophy that affects the upper body. However, the
contraction alone is not sufficient to cause disease, some-
thing that has puzzled researchers studying FSHD genetics.
A simple loss-of-function model doesn’t explain the fact
that patients with FSHD must have at least one copy of
the D4Z4 sequence present and that contraction has to
occur in the context of certain haplotype backgrounds.
The major transcript in the repeat is produced from
DUX4, which encodes a double homeobox protein,
although the transcripts from the repeat are reportedly
unstable. Lemmers et al. recently discovered evidence
that contraction of D4Z4 on a permissive background actu-
ally leads to a gain, rather than a loss, of function. They1Department of Human Genetics, Emory University School of Medicine, Atlan
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produced from FSHD-permissive haplotype backgrounds,
due to the creation of a polyadenylation signal. What
does the repeat contraction have to do with this? The
contraction is associated with DNA modifications that
open the chromatin structure and could be associated
with increased transcription of genes in this region.
Thus, cells from patients with FSHD would theoretically
producemore of the relevantDUX4 transcript and it would
stick around longer. The missing piece of this pathogenesis
puzzle is to figure out how more of this DUX4 transcript
leads to muscle wasting.
Lemmers et al. (2010) Science Express. Published online
August 19, 2010. 10.1126/science.1189044
Structural Polymorphism at 16p12.1 Influences
Microdeletion Risk
The large-scale methodologies that were used to sequence
the human genome made the project feasible but did not
have the finesse to unravel the true structure of some of
the more complicated segments of the genome. Antonacci
et al. create a better map of one such region, the segmental
duplication-rich 16p12.1, which they realized was assem-
bled in the wrong orientation in the human reference
assembly. The orientation was not the only issue; there
are, in fact, two common human haplotypes in this region
that differ by more than 300 kb of duplicated sequence,
making it one of the largest copy-number polymorphisms
identified to date in the human euchromatin. Beyond the
correction to the human reference assembly, this discovery
alters the locations of structural elements relative to the
breakpoints of a recurrent microdeletion that predisposes
one to intellectual disability. In fact, only the larger of
the two common haplotypes at 16p12.1 appears to be
susceptible to this deletion, because it alone contains
directly oriented duplications that could serve as substrates
for nonallelic homologous recombination.
Antonacci et al. (2010) Nature Genetics 42, 745–750.
10.1038/ng.643
Reversal of Mis-Fortune
If DNA mutations randomly occur and can cause a detri-
mental effect, is it not reasonable that they can also have
a positive effect and lead to correction of a defect? Sure,
reversion mutation is theoretically possible and has been
reported, albeit infrequently. Choate et al. recentlyta, GA 30322, USA
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reported a case in which mutation reversion is the rule,
rather than the exception. In ichthyosis with confetti
(IWC), the skin of affected individuals lacks integrity and
proper differentiation of the epidermal layers. However,
there are patches of normal-looking skin that can number
in the thousands, giving the appearance of confetti.
Through comparisons of DNA from the normal skin to
that from the blood and abnormal skin of the same
affected individuals, Choate et al. demonstrate that each
normal patch of skin in every affected individual has loss
of heterozygosity of a similar, but not identical, region of
chromosome 17q. They use this information to identify
mutations in the gene for keratin 10 as the cause of IWC
and to prove that each normal patch of skin represents
a separate reversion event of the original mutation. The
high rate of reversion, as well as the persistence of these
clones, indicates that there may be positive selection for
the revertant stem cell clones and/or increased mitotic
recombination in IWC. The unusual mutant protein
produced in the affected skin could play a role in the gener-
ation of or selection for revertants; all of the mutations
cause frameshifts into the same alternate reading frame,
which adds an arginine-rich C-terminal peptide to keratin
10, aberrantly directing it to the nucleolus.
Choate et al. (2010) Science Express. Published August 26,
2010. 10.1126/science.1192280
Plavix, Pharmacogenetics, and Prescriptions
The mainstay therapy for treatment of acute coronary
syndrome is a combination of aspirin and clopidogrel
(Plavix), a drug that inhibits platelet aggregation. It is esti-
mated that maybe one-quarter of people have a subthera-
peutic response to clopidogrel, due at least in part to
variation in the genes that govern uptake and metabolism450 The American Journal of Human Genetics 87, 449–450, Octoberof the drug. The FDA has required a statement to be added
to the clopidogrel label that warns that it might be less
effective in poor metabolizers, who are at least partly
defined by reduced function alleles in CYP2C19, a gene
encoding the enzyme that activates clopidogrel from its
prodrug form. Even so, CYP2C19 accounts for only
a minority of the variation in clopidogrel response, and
data suggest that response to the drug might also be
governed by variation in ABCB1, which encodes a drug
transporter. Two recent large studies add to the pharmaco-
genetic data on clopidogrel and on two newer platelet
inhibitors, prasugrel and ticagrelor, but do not clarify
the use of pharmacogenetic data in the prescription of
platelet inhibitors. These analyses, which are offshoots
of the TRITON-TIMI 38 and PLATO trials, provide further
support for the influence of CYP2C19 variation on risk of
cardiovascular death, heart attack, or stroke in patients
with acute coronary syndrome. Adding genotype infor-
mation for ABCB1, which is an independent risk factor,
seems as though it could improve the discrimination
between risk groups, but the two studies report opposite
risk effects for the same ABCB1 allele in people treated
with clopidogrel, making the utility of this information
unclear. What is still lacking for the pharmacogenetic
data on clopidogrel is to provide physicians with data
that suggest how the information should influence
prescription of the drug. Perhaps this will become
a moot point, because of the fact that prasugrel and tica-
grelor each outperformed clopidogrel in these studies in
all genotype groups.
Mega et al. (2010) Lancet. Published online August 29,
2010. 10.1016/S0140-6736(10)61273-1
Wallentin et al. (2010) Lancet. Published online August 29,
2010. 10.1016/S0140-6736(10)61274-3This Month in Our Sister JournalsChromosome 16p11.2 Deletions Are Associated with
Developmental Delay and Obesity
Chromosome 16p is rife with segmental duplications that
make it prone to rearrangement. Among the recurrent
mutations of 16p is a ~200 kb deletion at 16p11.2 in indi-
viduals with severe early-onset obesity, as reported earlier
this year (Bochukova et al. Nature 463, 666–670). In
Genetics in Medicine this month, Bachmann-Gagescu et al.
find the same recurrent deletion, but the pool of samples
from which they draw allows them to more broadly assess
the associated phenotype. Whereas the case sample used
by Bochukova et al. was defined by severe obesity, Bach-
mann-Gagescu et al. collect data from a sample of over23,000 patients referred for comparative genomic hybrid-
ization for a variety of reasons, and overlapping 16p11.2
deletions were found in 31 individuals. Although complete
phenotypic information was not available for most, four of
the six individuals on whom they were able to obtain addi-
tional clinical information were found to be obese, further
cementing the link between this deletion and obesity. All
of the six individuals also had developmental delay,
thereby also implicating the deletion in neurodevelop-
mental phenotypes.
Bachmann-Gagescu et al. (2010) Genetics in Medicine.
Published online August 30, 2010. 10.1097/GIM.
0b013e3181ef42868, 2010
